Compare CC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | URGN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2014 | 2016 |
| Metric | CC | URGN |
|---|---|---|
| Price | $12.67 | $24.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $16.20 | ★ $61.71 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,638,000,000.00 | $1,128,000.00 |
| Revenue This Year | $2.02 | $193.20 |
| Revenue Next Year | $3.83 | $64.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $10.44 | $16.50 |
| 52 Week High | $28.67 | $50.81 |
| Indicator | CC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 18.22 |
| Support Level | N/A | $18.28 |
| Resistance Level | $16.26 | $27.76 |
| Average True Range (ATR) | 0.64 | 2.03 |
| MACD | 0.05 | -0.75 |
| Stochastic Oscillator | 18.75 | 3.48 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.